Gran® (filgrastim)&Peglasta® (pegfilgrastim): Risk of capillary leak syndrome in patients with cancer (filgastrim&pegfilgastrim) and in healthy donors (filgastrim only)

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 06 August 2014

Description: The NPCB would like to alert healthcare professionals that cases of capillary leak syndrome (CLS) have been reported in recipients of filgrastim including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor cell mobilisation. CLS has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Patients and healthy donors should be monitored closely for CLS symptoms such as oedema, difficulty breathing, and tiredness. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by SmartMedicine Sdn. Bhd. in agreement with NPCB.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA